Privia Health Group, Inc. (PRVA) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PRVA Revenue Growth
Revenue Breakdown (FY 2025)
PRVA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
PRVA Revenue Analysis (2018–2025)
As of May 8, 2026, Privia Health Group, Inc. (PRVA) generated trailing twelve-month (TTM) revenue of $2.25 billion, reflecting exceptional growth of +25.8% year-over-year. The most recent quarter (Q1 2026) recorded $603.8 million in revenue, up 11.6% sequentially.
Looking at the longer-term picture, PRVA's 5-year compound annual growth rate (CAGR) stands at +21.0%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $2.12 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows PRVA's business is primarily driven by FFS-Patient Care (64%), Capitated Revenue (15%), and Shared Savings (11%). With over half of revenue concentrated in FFS-Patient Care, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AGIO (+78.3% YoY), CNC (+17.0% YoY), and ALHC (+41.8% YoY), PRVA has underperformed the peer group in terms of revenue growth. Compare PRVA vs AGIO →
PRVA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PRVACurrent | $2.2B | +25.8% | +21.0% | 1.6% | |
 AGIO | $54M | +78.3% | - | -873.9% | |
 CNC | $194.8B | +17.0% | +11.9% | -3.9% | |
 ALHC | $3.9B | +41.8% | +32.7% | 0.4% | |
 OSCR | $11.7B | +31.9% | +81.8% | -3.4% | |
 DOCS | $570M | +15.9% | +37.4% | 39.9% |
PRVA Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.12B | +22.3% | $209.4M | 9.9% | $34.2M | 1.6% |
| 2024 | $1.74B | +4.7% | $176.9M | 10.2% | $17.0M | 1.0% |
| 2023 | $1.66B | +22.2% | $161.5M | 9.7% | $20.6M | 1.2% |
| 2022 | $1.36B | +40.4% | $134.8M | 9.9% | $-19,122,000 | -1.4% |
| 2021 | $966.2M | +18.3% | $63.7M | 6.6% | $-217,436,000 | -22.5% |
| 2020 | $817.1M | +3.9% | $82.6M | 10.1% | $25.4M | 3.1% |
| 2019 | $786.4M | +19.6% | $68.5M | 8.7% | $16.1M | 2.0% |
| 2018 | $657.6M | - | $56.5M | 8.6% | $2.2M | 0.3% |
See PRVA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRVA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRVA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPRVA — Frequently Asked Questions
Quick answers to the most common questions about buying PRVA stock.
Is PRVA's revenue growth accelerating or slowing?
PRVA revenue is accelerating at +25.8% year-over-year, exceeding the 5-year CAGR of +21.0%. TTM revenue reached $2.2B. Growth momentum has increased versus prior periods.
What is PRVA's long-term revenue growth rate?
Privia Health Group, Inc.'s 5-year revenue CAGR of +21.0% reflects the sustained expansion pattern. Current YoY growth of +25.8% is above this long-term average.
How is PRVA's revenue distributed by segment?
PRVA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.